"Patients who experience hyperkalemia while on RAAS inhibitor therapy may benefit from intensification of other evidence-based preventative measures against adverse cardiorenal outcomes, such as lipid ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

WASHINGTON -- Use of the potassium-binding agent patiromer (Veltassa) allowed more heart failure patients at risk for hyperkalemia to remain on optimal therapy with renin-angiotensin-aldosterone ...

Credit: Getty Images. The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi. In patients with diabetic kidney disease, use of 2 classes of ...

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

A sick child taking medication Real-world data on use of RAAS inhibitors can be used to support future pragmatic studies to optimize management of childhood-onset SLE, according to investigators.

Uptitration of renin-angiotensin-aldosterone system (RAAS) inhibitors was less successful in women than men with acute heart failure (AHF), especially in those with HF with reduced ejection fraction.

A multi-center study of more than 3,000 people with high blood pressure and brain aneurysms found that the use of RAAS inhibitors, a class of blood pressure lowering medications, reduced the risk of ...

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...